ABSTRACT: Cardiovascular disease (CVD) risk factors are well established. However, little is known about a woman’s cardiovascular response to pregnancy, which appears to be an early marker of future maternal CVD risk. Spontaneous preterm delivery (sPTD) has been associated with a ≤3-fold increased risk of maternal CVD death later in life compared with having a term delivery. This review focuses on 3 key areas to critically assess the association of sPTD and future maternal CVD risk: (1) CVD risk factors, (2) inflammatory biomarkers of interest, and (3) specific forms of vascular dysfunction, such as endothelial function and arterial stiffness, and mechanisms by which each may be linked to sPTD. The association of sPTD with subsequent future maternal CVD risk suggests that a woman’s abnormal response to pregnancy may serve as her first physiological stress test. These findings suggest that future research is needed to understand why women with sPTD may be at risk for CVD to implement effective interventions earlier in a woman’s life.

Cardiovascular disease (CVD) is the number 1 killer of women despite advancement in life-saving therapies. Women who experience adverse pregnancy outcomes such as preterm delivery, preeclampsia, gestational hypertension, intrauterine growth restriction, and gestational diabetes mellitus are at increased risk of future CVD. More recently, adverse pregnancy outcomes such as spontaneous preterm delivery (sPTD) have been identified as a risk factor for future CVD risk.

Normal Pregnancy

Recent literature has suggested that an otherwise healthy woman who is unable to carry her baby full-term has therefore experienced an abnormal physiological stress test. Hemodynamic changes occur in a woman’s body during and after pregnancy. Both blood volume and red blood cell mass increase during pregnancy, leading to increased preload. Cardiac output increases by 20% to 50%, starting as early as 5 weeks of gestation and peaking by mid- to late pregnancy. These gradual increases in cardiac output, heart rate, and systolic blood pressure over months of pregnancy are in some ways similar to the acute responses observed during exercise stress testing. Reversal can be seen as early as 2 weeks postpartum, again comparable to those cardiovascular changes seen acutely during the recovery period of an exercise stress test. Hypothetically, the pregnancy response may serve as a window into future maternal CVD risk.
Preterm Delivery

Preterm delivery is a common adverse pregnancy outcome that affects 9.6% of women who give birth in the United States.9 There are 2 primary types of preterm delivery: spontaneous and medically indicated. Approximately 75% of preterm deliveries are the result of sPTD.10 Spontaneous preterm delivery results from either preterm labor, which leads to delivery, or premature spontaneous rupture of membranes, which leads to preterm delivery.10 In contrast, medically indicated preterm delivery is an intended preterm delivery for maternal or fetal indications, such as preeclampsia or nonreassuring fetal status.10 Medically indicated preterm delivery has been associated with arterial stiffness and a ≤8-fold increased future maternal CVD risk.2 For both sPTD and medically indicated preterm delivery, an inverse relationship exists between gestational age at delivery and increased maternal CVD risk.11 However, less is known about the association of sPTD with subsequent future maternal CVD risk.

In this focused review, we discuss potential mechanistic pathways that could account for this association between sPTD and subsequent CVD. We focus on 3 key areas that pertain to sPTD and future maternal CVD risk: (1) CVD risk factors, (2) inflammatory biomarkers, and (3) specific forms of vascular dysfunction such as endothelial function and arterial stiffness.

ASSOCIATION OF PRETERM DELIVERY AND FUTURE MATERNAL CVD

sPTD Versus Medically Indicated Preterm Delivery and CVD

In a landmark population-based cohort study, researchers reported that mothers with no preeclampsia but a preterm delivery experienced a 2.95-fold increased risk of CVD death compared with controls over a 25-year follow-up period.2 In addition, women with preeclampsia were divided into 2 groups based on whether the mother delivered at term or preterm. Women with term preeclampsia were at a 1.65-fold increased risk of CVD death compared with women without preeclampsia. Women with preterm delivery and preeclampsia experienced an 8.12-fold higher risk of CVD death, independent of lifestyle or other socioeconomic variations.2 Otherwise healthy women who present with premature spontaneous rupture of membranes or an early delivery (a gestational age of <37 weeks) have a ≤3-fold increased risk of CVD-related death later in life.2 More recent reports demonstrate increased rates of ischemic heart disease (IHD) and associated death, hospitalizations, and CVD mortality in sPTD.12-15 From 2000 to 2017, 14 studies (Table) examined cardiovascular outcomes and demonstrated death rates to be 1.5- to 3-fold higher for women with all preterm delivery compared with women who deliver at term after adjusting for age, hypertensive disorders, and diabetes mellitus.14 Recent studies have further demonstrated increased maternal CVD risk in as little as 5 years postpartum.25

In comparing medically indicated preterm delivery and sPTD in their association with later maternal IHD risk, Hastie et al12 found that both sPTD and medically indicated preterm delivery had strong associations with subsequent IHD (hazard ratio [HR], 2.26; 95% confidence interval [CI], 1.88–2.71) and total IHD events (HR, 1.58; 95% CI, 1.47–1.71), with stronger associations related to medically indicated preterm delivery compared with spontaneous preterm delivery (P=0.005). However, among sPTD, the association with IHD mortality was much stronger for extreme (24–32 weeks gestation) preterm delivery (HR, 3.23; 95% CI, 2.17–4.80) than mild to moderate (33–36 weeks gestation) preterm delivery (HR, 1.85; 95% CI, 1.41–2.44; P=0.022).12

Women with medically indicated preterm delivery tend to be older, more likely to have adverse pregnancy outcomes such as gestational hypertension and preeclampsia, and more likely to deliver smaller infants, whereas women with sPTD are more likely to be younger, do not have preeclampsia, more likely to deliver higher birthweight infants, and more likely to be of lower socioeconomic status. As the age at first IHD event decreased, the association between preterm delivery and an IHD event increased.15 Kessous et al15 also investigated the relationship of preterm delivery with later increased risk for cardiovascular morbidity. At 10-year follow up, patients with preterm delivery had higher rates of CVD and higher rates of total CVD-related hospitalizations, with a linear association between the number of previous preterm deliveries and the future risk for cardiovascular hospitalizations (5.5% for ≥2 preterm deliveries; 5.0% for 1 preterm delivery versus 3.5% in the comparison group; P<0.001).15 Most recently, Pariente et al26 reported that women who had sPTD were at an increased risk of subsequent long-term maternal kidney disease, which in turn may interplay with mortality from CVD.26

CVD and Preterm Delivery Associated With Other Adverse Pregnancy Outcomes

Adverse pregnancy outcomes have been identified as a CVD risk marker, both in US and European cardiovascular guidelines.27,28 In addition to established adverse pregnancy outcomes such as preeclampsia, small for gestational age, gestational hypertension, and gestational diabetes mellitus, sPTD is associated with maternal CVD risk whether sPTD is independent or compounded by other adverse pregnancy out-
comes.2 Bonamy et al11 identified small for gestational age as a contributor to CVD risk in mothers with preterm delivery. Compared with mothers who delivered at term, mothers with preterm delivery complicated by small for gestational age had a higher risk of subsequent CVD (HR, 1.39–2.57; P<0.001).11 Mothers of very small for gestational age (based on the Swedish reference curve for intrauterine growth <0.75) infants experienced an elevated HR of 1.38 to 3.40. In addition, the earlier the delivery, the more significantly the small for gestational age appeared to contribute to higher maternal CVD risk.29

In summary, we have compiled 14 studies (Table) with CVD outcomes, including nonfatal myocardial infarction, revascularization, cardiovascular death, stroke, thromboembolism, IHD-related hospitalizations, and death related to IHD in women, which includes medically indicated and sPTD and studies that adjusted for risk factors at study entry and during follow-up. The totality of this evidence suggests that all-cause preterm delivery (medically indicated and sPTD) is associated with a 1.5- to 3-fold independent, increased risk of cardiovascular morbidity and mortality after controlling for some CV-related risk factors. The more recent, larger studies suggest that sPTD is an independent predictor of future CVD risk despite better designs that controlled for multiple CVD risk factors. Notably, the HR (1.4–1.9) strengthened as more CVD risk factors were controlled for in the analysis, suggesting that sPTD may be an independent CVD risk predictor.13,15

Table. Preterm Delivery and Associated CVD Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of PTD</th>
<th>Sample (N)</th>
<th>CVD Variables*</th>
<th>HR</th>
<th>CI</th>
<th>Follow-Up, y</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smith et al,16 2000</td>
<td>PTD &lt;37 wk</td>
<td>114</td>
<td>Hypertension during pregnancy</td>
<td>2.1</td>
<td>1.2–3.5</td>
<td>Retrospective 1954–1963</td>
<td>CV death</td>
</tr>
<tr>
<td>Irgens et al,2  2001</td>
<td>PTD &lt;36 wk</td>
<td>5157</td>
<td>Age, PreE</td>
<td>1.6</td>
<td>1.4–1.8</td>
<td>25 y</td>
<td>All death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.0</td>
<td>2.1–4.1</td>
<td></td>
<td>CV death</td>
</tr>
<tr>
<td>Smith et al,17  2001</td>
<td>PTD &lt;36 wk</td>
<td>7315</td>
<td>Age, PreE, HTN</td>
<td>1.8</td>
<td>1.3–2.5</td>
<td>15–19 y</td>
<td>IHD hospitalization or death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.9</td>
<td>0.7–4.9</td>
<td></td>
<td>IHD death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.5</td>
<td>1.2–1.8</td>
<td></td>
<td>All death</td>
</tr>
<tr>
<td>Pell et al,16  2004</td>
<td>PTD &lt;36 wk</td>
<td>6768</td>
<td>Age, PreE, HTN</td>
<td>1.9</td>
<td>1.4–2.7</td>
<td>14–19 y</td>
<td>Cerebrovascular events</td>
</tr>
<tr>
<td>Nardi et al,18  2006</td>
<td>PTD &lt;32 wk</td>
<td>23</td>
<td>Age, HTN, CHO, DM, BMI, smoking status</td>
<td>2.1</td>
<td>1.1–4.1</td>
<td>Retrospective 1990–2000</td>
<td>Nonfatal MI and death as a result of IHD</td>
</tr>
<tr>
<td>Catov et al,20  2007</td>
<td>PTD &lt;37 wk</td>
<td>27</td>
<td>Age, race, BP, HDL, smoking status, statin use</td>
<td>2.9</td>
<td>1.2–6.9</td>
<td>Retrospective prior PTD 57 y ago</td>
<td>CVD (MI, stroke, angina, CABG, angioplasty, peripheral vascular disease)</td>
</tr>
<tr>
<td>Catov et al,21  2010</td>
<td>PTD &lt;37 wk</td>
<td>25688</td>
<td>Age, PreE, DM, GDM</td>
<td>2.0</td>
<td>1.7–2.3</td>
<td>Retrospective 1973–2006</td>
<td>CVD mortality</td>
</tr>
<tr>
<td>Lykke et al,22  2010a</td>
<td>PTD &lt;37 wk</td>
<td>41659</td>
<td>Age, prepregnancy CVD, DM, PreE</td>
<td>2.0</td>
<td>1.6–2.4</td>
<td>Retrospective 1978–2007</td>
<td>CV death</td>
</tr>
<tr>
<td>Lykke et al,23  2010b</td>
<td>PTD &lt;37 wk</td>
<td>1608</td>
<td>Age, HTN, PreE</td>
<td>1.4</td>
<td>1.02–1.81</td>
<td>Retrospective 1978–2007</td>
<td>HTN, thromboembolism, DM, IHD</td>
</tr>
<tr>
<td>Hastie et al,12 2011</td>
<td>sPTD &lt;36 wk</td>
<td>29965</td>
<td>Age, HTN, PreE</td>
<td>1.5</td>
<td>1.31–1.72</td>
<td>22</td>
<td>IHD events</td>
</tr>
<tr>
<td>Bonamy et al,11 2011</td>
<td>PTD &lt;37 wk</td>
<td>56893</td>
<td>Age, prior CVD, DM, GDM, HTN, PreE, smoking status</td>
<td>1.4</td>
<td>1.2–1.64</td>
<td>Retrospective 1983–2005</td>
<td>CV hospitalizations or death (coronary heart disease, cerebrovascular events, heart failure</td>
</tr>
<tr>
<td>Kessous et al,15 2013</td>
<td>sPTD &lt;34 wk</td>
<td>5992</td>
<td>Age, PreE, DM, obesity</td>
<td>1.4</td>
<td>1.2–1.6</td>
<td>10–20</td>
<td>CV hospitalizations</td>
</tr>
<tr>
<td>Rich-Edwards et al,13 2015</td>
<td>sPTD &lt;37 wk</td>
<td>33230</td>
<td>Age, PreE, GDM, DM, smoking, obesity</td>
<td>1.9</td>
<td>1.6–2.2</td>
<td>24.8</td>
<td>CVD mortality</td>
</tr>
<tr>
<td>Ngo et al,14 2015</td>
<td>sPTD &lt;37 wk</td>
<td>38435</td>
<td>Age, GDM, smoking, HTN, GHTN</td>
<td>1.53</td>
<td>1.35–1.72</td>
<td>7.5</td>
<td>CVD</td>
</tr>
</tbody>
</table>

BP indicates blood pressure; CHO, cholesterol; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; DM, diabetes mellitus; GDM, gestational diabetes; GHTN, gestational hypertension; HDL, high-density lipoprotein; HR, hazard ratio; HTN, hypertension; IHD, ischemic heart disease; PreE, preeclampsia; PTD, preterm delivery; and sPTD, spontaneous preterm delivery.

*CVD variable list: age, HTN, PreE, GHTN, GDM, DM, CHO, statin use, smoking status, obesity, and diabetes mellitus. All variables were matched, excluded, or controlled for.
CVD RISK FACTORS AND PRETERM DELIVERY

Currently, 4 risk factors are shared by preterm delivery and future maternal CVD risk: (1) smoking, (2) hypertension, (3) diabetes mellitus, and (4) African American descent. In the 2011 Prevention of Cardiovascular Disease in Women Update, adverse pregnancy outcomes such as hypertension in pregnancy, preeclampsia, and gestational diabetes mellitus were characterized as novel CVD risk predictors. Less understood is the impact of known CVD risk biomarkers such as cholesterol and glucose in the setting of sPTD and subsequent future maternal CVD risk. These risk factors include total cholesterol (TC), high-density lipoprotein, low-density lipoprotein, and triglycerides, which are measured for CVD risk prevention traditionally in non-pregnant, midlife women. These important risk factors may potentially play a role in the earlier identification of women who experience sPTD and are at future increased CVD risk.

In uncomplicated pregnancies, a steady rise occurs in major lipoproteins, and these levels peak near term delivery. In uncomplicated pregnancies, neither TC nor triglyceride is >250 mg/dL at any time. Eleven studies have investigated the relationship of cholesterol levels to preterm delivery and sPTD. Mudd et al found an increased incidence of sPTD among women with higher TC, elevated low-density lipoprotein, and higher triglycerides. It is interesting to note that they found positive associations of lower TC, high-density lipoprotein, and low-density lipoprotein levels in the medically indicated preterm delivery cohort. Magnussen et al prospectively evaluated the Norwegian population study known as the Nord-Trøndelag Health Study from the Medical Birth Registry of Norway. After adjusting for hypertensive disorders in pregnancy, they found a positive association with preterm delivery and preterm delivery dyslipidemia. Triglycerides >141.6 mg/dL were associated with a 60% higher risk of preterm delivery, although lower levels of triglycerides (<62 mg/dL) were not associated with preterm delivery. Furthermore, higher levels of TC, triglycerides, and glucose correlated with lower gestational age at preterm delivery. These findings are similar to those of Mudd et al, although Magnussen et al included women with impaired glucose, a known maternal CVD risk factor. The general theme of these studies is that dyslipidemia is prevalent in women who experience preterm delivery before, during, or after pregnancy.

Dyslipidemia prepregnancy and during pregnancy have been associated with increased sPTD risk. Ca-tov et al reported that women with dyslipidemia in early pregnancy were 2.8 times more likely to deliver before 34 weeks after adjusting for race, body mass index, education, and family history of hypertensive disorders of pregnancy. There were significant linear trends for both TC and low-density lipoprotein as dyslipidemia progressed and sPTD severity increased. In a subset of patients from the Coronary Artery Risk Development in Young Adults study, investigators reported a U-shaped relationship curve between prepregnancy cholesterol and preterm birth risk. Prepregnancy triglycerides in the highest quartile (>195 mg/dL) were associated with preterm delivery <34 weeks in women without hypertension. Preterm birth risk was also seen in the lowest quartile (TC <156 mg/dL). These rates were independent of ethnicity, age, parity, body mass index, hypertension during pregnancy, physical activity, and years from measurement to birth.

INFLAMMATORY BIOMARKERS AND PRETERM DELIVERY

Currently, data on the applicability of inflammatory markers such as C-reactive protein (CRP) in the utility of predicting all preterm delivery or CVD are limited. This may be because parturition is an inflammatory process, therefore questioning the utility of this widely used cardiovascular risk marker. However, higher elevations of CRP have been suggested to correlate with preterm delivery. Interleukin-6 has potential as an emerging biomarker in women with adverse pregnancy outcomes; however, its applicability to women with sPTD is less understood.

CRP

Serum CRP is an inflammatory biomarker, acute-phase protein secreted by the liver in response to inflammation. In addition, markers of inflammation for diagnosis or treatment in this patient population have limited clinical applicability. Pitiphat et al investigated CRP in preterm women and matched controls. They found an association among presence of infection, elevated CRP, and subsequent development of sPTD. Other studies confirmed the association of elevated CRP with increased risk of preterm delivery. These findings indicate that the higher CRP values are associated preterm delivery. Catov et al investigated CRP, cholesterol, and their association with sPTD. They concluded that early onset inflammation and dyslipidemia during pregnancy were independently associated with sPTD from 34 to 37 weeks. It is interesting to note that the presence of both conditions increased risk of sPTD at <34 weeks 6.4-fold (95% CI, 1.7–24.1).

C-Reactive Protein in the Years After Delivery

Mechanistically, different pathways are responsible for elevated CRP later in life compared with during pregnancy and in the immediate postpartum setting where there may be an infection. Studies in this area have
yielded mixed results. Hastie et al12 completed a retrospective cohort study to compare later maternal CRP (mean period=13 years after delivery) among women who had previous sPTD, those who had medically indicated preterm delivery, and those with term births. After adjusting for potential cofounders, the investigators41 reported an elevation in CRP for the medically indicated preterm group compared with term births but not for the sPTD group. CRP levels in women with sPTD over time were not significantly higher than those of women with term deliveries. Catov et al42 reported similar findings in longer term follow-up. Women with a history of preterm delivery 4 to 12 years postpartum had no difference in CRP or interleukin-6.

Interleukin-6
Dulay et al43 found that maternal blood interleukin-6 and CRP levels were higher in women with subclinical intraamniotic infection compared with time-matched controls. However, the investigators noted an overlap with CIs, leading to difficulty in the interpretation of these results clinically. A systematic review further suggested that interleukin-6 and CRP are measurable in midtrimester cervicovaginal fluid but not in maternal blood samples, suggesting a localized, not a systemic, inflammatory process.44

VASCULAR FUNCTION IN PRETERM DELIVERY
Limited studies have evaluated vascular function in preterm delivery; however, those available indicate that an abnormal vascular response to pregnancy and subsequent delivery may be an early warning sign for the development of future maternal CVD.42,45–47 Novel noninvasive methods to assess arterial stiffness, including pulse wave velocity and augmentation index during normal pregnancy,48,49 are now available to extend the initial work in women with adverse pregnancy outcomes through this noninvasive vascular function test.

Preterm Delivery and CVD Risk
Pulse-wave velocity is considered the gold standard in the assessment of arterial stiffness noninvasively. Pulse-wave velocity directly measures the more elastic, aortoiliac pathway and has been previously described as being most clinically relevant as the aorta and its branches are in closest proximity to the left ventricle and are mostly responsible for pathophysiological effects of arterial stiffness. Augmentation index measures atrial stiffness via vascular smooth muscle and smaller artery tone.50 Pulse-wave velocity and augmentation index are complementary but not interchangeable. In an initial report of the use of noninvasive pulse-wave velocity and augmentation index in the context of sPTD, Khalil et al46 studied arterial stiffness in women with all preterm deliveries compared with controls at 11 to 13 weeks of gestation and compared 3 cohorts: (1) medically indicated preterm delivery, (2) sPTD, and (3) term deliveries. They found that women with medically indicated preterm delivery had significantly higher arterial stiffness (increased augmentation index but no difference in pulse-wave velocity) than women with sPTD and term delivery46 and lower augmentation index in sPTD <34 weeks.46 There are limited data assessing differences in vascular stiffness in women with sPTD during pregnancy and the postpartum period. A potential hypothesis for the Khalil et al46 finding may be that sPTD has a different vascular response than other adverse pregnancy outcomes, indicating an alternative mechanistic pathway that warrants additional inquiry. Catov et al42 reported that women with a history of preterm delivery 4 to 12 years postpartum had no difference in pulse wave velocity or endothelial function compared with controls. These data support the findings that women with sPTD are less likely to have arterial stiffness and more likely to have an alternative vascular mechanistic pathway.

KNOWLEDGE GAPS
Important knowledge gaps remain regarding the utility of adverse pregnancy outcomes in the prediction of CVD in women. We have identified the following unanswered questions to improve these gaps: (1) To what extent does a history of pregnancy complications influence the need for an earlier CVD risk assessment? (2) Should lifestyle modification be recommended to women who had preterm delivery? (3) To what extent does a history of pregnancy complication or sPTD specifically predict CVD independently of all measured risk factors used in CVD risk scores? If fully independent, is it at a level to meaningfully alter risk score calculations? If not, which usual risk factors (via adjustments) best explain (ie, via significant attenuation of HR) association of history of sPTD and CVD outcomes? (4) Can any lifestyle intervention after pregnancy lead to lessening of the future risk of sPTD? Future research will advise further investigation to provide evidence to further shape current national guidelines.

LIMITATIONS
Reviews of the literature are limited by potential publication bias because negatively associated studies are generally not published and therefore not included in the current body of knowledge.
CONCLUSIONS
A growing body of evidence suggests that both medically indicated and sPTD are independent predictors of women at risk for future CVD.\textsuperscript{11,13} sPTD is associated with higher systolic blood pressure and lower high-density lipoprotein. Although these associations may be caused by preexisting conditions exacerbated by pregnancy, they also may be related to differences in mechanistic pathways. In addition, sPTD may label high-risk women for more vigilant CVD lifestyle interventions. Further investigation is needed to understand the role of inflammatory biomarkers for early identification of CVD risk in women with sPTD.

ARTICLE INFORMATION
Correspondence
Margo B. Minissian, PhD, Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, 127 San Vicente Blvd, Suite A9304 AHSP, Los Angeles, CA 90048. Email MinissianM@cshs.org

Affiliations
Barbra Streisand Women’s Heart Center, Cedars-Sinai Heart Institute (M.B.M., J.W., C.L.S., C.N.B.M.), Brawerman Nursing Institute (M.B.M.), and Department of Obstetrics and Gynecology (S.K., E.E.A.), Cedars-Sinai Medical Center, Los Angeles, CA. School of Nursing, University of California, Los Angeles (M.B.M., J.E., W.A.R., L.V.D.).

Sources of Funding
This work was supported by the National Institutes of Health (F31NR015725), the Clinical and Translational Science Institute (UL1TR000124 and UL1TR001881-01), and the Preventive Cardiovascular Nurses Association through the Cedars-Sinai Department of Obstetrics and Gynecology, the Cedars-Sinai Barbra Streisand Women’s Heart Center, Cedars-Sinai Heart Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosures
None.

REFERENCES


Association of Spontaneous Preterm Delivery and Future Maternal Cardiovascular Disease
Margo B. Minissian, Sarah Kilpatrick, Jo-Ann Eastwood, Wendie A. Robbins, Eynav E. Accortt, Janet Wei, Chrisandra L. Shufelt, Lynn V. Doering and C. Noel Bairey Merz

Circulation. 2018;137:865-871
doi: 10.1161/CIRCULATIONAHA.117.031403
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2018 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/137/8/865

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/